HELP Therapeutics

iPSC-derived cardiomyocyte cell therapy

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Cardiac cell therapyCell therapy
Heart Failure

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Est. primary completion 2027-06-30 · NCT07496372 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
HiCM-188 (allogeneic iPSC-cardiomyocytes)Phase 1/2Advanced Heart Failure, Ischemic Heart Failure
Est. primary completion 2028-02 · NCT07646210 · CT.gov ↗
What to watch
October 2028 (1)
HiCM-188 (allogeneic iPSC-cardiomyocytes)Phase 1/2Ischemic Heart Failure, CABG-patients
Est. primary completion 2028-10-20 · NCT07471698 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.